

## Special Issue

# Research on Malaria Immunology in Animal Models

### Message from the Guest Editors

This Special Issue will focus on new and established animal models of *Plasmodium* infection that can be used to interrogate the immunobiology of malaria. The goal is to provide a collection of articles that will focus on the recent scientific and technical progress made in this field. Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation or review, to highlight (i) new animal models of malaria, (ii) new insights into the immunobiology of malaria using animal models and (iii) recent advances in novel prophylactic and therapeutic vaccines in animal models of malaria. Keywords:

- malaria
- *Plasmodium* infection
- non-human primate models
- mouse models
- immunology
- vaccines
- innate immunity
- adaptive immunity
- anti-parasite immunity
- clinical immunity

---

### Guest Editors

Dr. Tracey J. Lamb

Department of Pathology, The University of Utah, Salt Lake City, UT  
84112, USA

Dr. Chester J. Joyner

Center for Vaccines and Immunology, University of Georgia, Athens, GA  
30602, USA

---

### Deadline for manuscript submissions

closed (30 September 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/54531](https://mdpi.com/si/54531)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).